Your browser doesn't support javascript.
loading
Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.
Vigna, G B; Donega, P; Passaro, A; Zanca, R; Cattin, L; Fonda, M; Pauciullo, P; Marotta, G; Fellin, R; Gasparrini, S; Piliego, T.
Afiliación
  • Vigna GB; Institute of Internal Medicine, University of Trieste, Italy.
Nutr Metab Cardiovasc Dis ; 9(5): 234-43, 1999 Oct.
Article en En | MEDLINE | ID: mdl-10656170
BACKGROUND AND AIM: Impaired triglyceride-rich lipoprotein metabolism is most probably related to an enhanced cardiovascular risk, and may be associated with a pro-coagulant state. A double-blind, randomized study was undertaken to evaluate two widely utilized hypolipidemic drugs in the post-prandial phase and their impact on lipid, coagulation and fibrinolytic parameters. METHODS AND RESULTS: Thirty middle-aged men selected according to their low density lipoprotein-cholesterol (LDL-C) > or = 160 and < or = 240 mg/dl and borderline hypertriglyceridemia (110-220 mg/dl) after at least one month of a lipid-lowering diet received gemfibrozil (600 mg bid) or simvastatin (20 mg qd) and the corresponding placebo. On enrollment and after 2 months of drug treatment, they were tested with a standard oral fat load (OFL) (35 g fat/m2 body surface). On both occasions plasma total-cholesterol, LDL-C, HDL-C, triglycerides, lipoprotein[a] (Lp[a]), tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), antithrombin-III (AT-III), plasminogen and fibrinogen were determined just before the meal (t0) and at times 2 hours, 4 h, 6 h, 8 h after it (t2-t8). A two-factor (time and visit) multivariate analysis for repeated measurements was performed to evaluate the data. Total cholesterol, and LDL-C were significantly diminished 2 months after both gemfibrozil and simvastatin, the latter being more active. Plasma triglycerides showed a marked reduction with gemfibrozil at all times, while simvastatin regimen yielded only minor modifications. HDL-C was only slightly increased by simvastatin; Lp[a] plasma levels were almost unaffected. Small fibrinogen (t0, t2, t6, t8), PAI-1 (t6) and AT III (t0-t8) increases were observed after gemfibrozil, while simvastatin did not significantly modify these parameters. CONCLUSIONS: In the post-prandial phase, gemfibrozil and simvastatin induce different metabolic effects that beneficially influence the lipid pattern, whereas fibrinolytic and coagulative parameters display minor variations of undetermined significance.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Gemfibrozilo / Hipertrigliceridemia / Simvastatina / Hipercolesterolemia / Hipolipemiantes Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Nutr Metab Cardiovasc Dis Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / CIENCIAS DA NUTRICAO / METABOLISMO Año: 1999 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Países Bajos
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Gemfibrozilo / Hipertrigliceridemia / Simvastatina / Hipercolesterolemia / Hipolipemiantes Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Nutr Metab Cardiovasc Dis Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / CIENCIAS DA NUTRICAO / METABOLISMO Año: 1999 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Países Bajos